New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:06 EDTITCIIntra-Cellular announces initiation of Phase I/II clinical trial for ITI-007
Intra-Cellular announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease. The commencement of this study marks an important milestone in our strategy to develop low doses of ITI-007 for the treatment of behavioral disturbances associated with dementia and related disorders.
News For ITCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
09:43 EDTITCIIntra-Cellular refusal to share ITI-007 poster 'unusual,' says The Street
Subscribe for More Information
06:20 EDTITCIIntra-Cellular could trade to $60-$80 on positive data, says Leerink
Subscribe for More Information
July 27, 2015
10:40 EDTITCILeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTITCIIntra-Cellular participates in a conference call with Leerink
Leerink Major Pharmaceuticals Analyst Fernandez, along with Biotech Vice President Matteis, host a conference call with Intra-Cellular President & CEO Mates, Clinical Development VP Vanover and Clinical Affairs VP O'Gorman to discuss ITI-007 in schizophrenia, bipolar depression and other indications on July 30 at 2 pm.
July 22, 2015
08:07 EDTITCIIntra-Cellular announces Phase 3 clinical development program
Subscribe for More Information
July 21, 2015
07:26 EDTITCIIntra-Cellular shares should advance significantly, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use